# Allinaire Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allinaire-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cleveland, US
- Website: www.allinaire.com
- Latest round: Seed (Jan 26, 2017)
- Investors on record: 3

## About

Allinaire Therapeutics LLC focuses on developing innovative humanized monoclonal antibodies targeting endothelial monocyte activating polypeptide II (EMAP II) for the treatment of cardiopulmonary diseases, particularly pulmonary arterial hypertension.Founded in 2016 and headquartered in Cleveland, US, Allinaire Therapeutics LLC is dedicated to the development of therapeutic solutions for pulmonary arterial hypertension and related conditions. The company was established by individuals with a commitment to advancing healthcare through specialized research. Douglas Hay serves as the CEO. Allinaire has engaged in one deal, with the most recent funding round occurring on January 26, 2017.Allinaire Therapeutics specializes in developing humanized monoclonal antibodies targeting endothelial monocyte activating polypeptide II (EMAP II), aiming to provide treatments for pulmonary arterial hypertension (PAH) and other cardiopulmonary diseases. The company conducts research on EMAP II, which acts as a non-classical cytokine involved in apoptosis and inflammation. Their products are in preclinical and clinical stages, targeting healthcare providers and patients in North America and Europe, where there is a significant demand for innovative cardiopulmonary treatments.Allinaire Therapeutics generates revenue through partnerships with research institutions and biopharmaceutical companies, focusing on the development of their EMAP II monoclonal antibodies. They engage in collaborative agreements for research and clinical trials, receiving funding and milestone payments as their therapeutic candidates progress. The company’s business model emphasizes collaboration over direct-to-consumer sales, linking revenue sources to the advancement of its therapeutic candidates through clinical development phases.Allinaire Therapeutics plans to utilize the funding raised in January 2017 to support the advancement of its EMAP II monoclonal antibodies through clinical development. The company is focused on expanding its product offerings in the therapeutic areas of pulmonary arterial hypertension, chronic obstructive pulmonary disease, and viral-induced acute lung injury. They aim to penetrate markets in North America and Europe with their innovative products, enhancing the treatment landscape for cardiopulmonary diseases.

## Funding rounds

- Seed, Jan 26, 2017 — BioCrossroads, BioMotiv, Innovate Indiana Fund

## Investors

- BioCrossroads (https://capitalatlas.ai/funds/biocrossroads) — Seed
- BioMotiv — Seed
- Innovate Indiana Fund — Seed